Abstract
Multiple Myeloma (MM) is a malignancy of the antibodyproducing plasma cells found in the bone marrow [1]. In recent years, we have witnessed significant improvements made in both the diagnostic criteria and novel therapies for MM, resulting in the prolonged survival of MM patients.
Highlights
Multiple Myeloma (MM) is a malignancy of the antibodyproducing plasma cells found in the bone marrow [1]
BH3 profiling of the sPCL sample demonstrated a response to the BAD peptide and ABT-199, consistent with BCL-2 dependence
This Bcl-2 dependence was confirmed by assessing sensitivity to ex-vivo BH3 mimetic treatment by flow cytometry
Summary
Multiple Myeloma (MM) is a malignancy of the antibodyproducing plasma cells found in the bone marrow [1]. CAR T cell therapy has been FDA approved for MM treatment [4] Despite these advancements, MM remains an incurable cancer with suboptimal overall survival, with many patients developing relapsed/refractory MM. The present diagnostic criteria for PCL include the number of circulating plasma cells exceeding 2 x 109/L and/or >20% plasma cells in the total leucocyte count [6] In both forms, PCL clinically resembles late-stage MM, with patients experiencing anemia, bone marrow failure, recurring bacterial infections renal insufficiency and hyperviscosity. Owing to the rarity of this disease, data is limited with regards to therapeutic options This underlines the importance of individual case reports and small case series for secondary PCL, as they aid the advancement of therapeutic treatment options for this difficult and challenging disease
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
